“…OTX2 mutations are associated with variable pituitary phenotypes, with no genotype-phenotype correlation (Dateki et al 2010). In most cases, premature protein termination was predicted, either via a nonsense mutation creating a stop codon (p.Q99X, p.Y179X, (Ragge et al 2005); p.Q97X, p.Y31X, (Wyatt et al 2008); p.S318X, (Henderson et al 2009); p.G188X, (Dateki et al 2010) or a frameshift (c.81delC, c.117delCC, c.464insGC, (Ragge et al 2005; c.106dupC, c.371_372 delAG, (Wyatt et al 2008); c.402_403insC, (Dateki et al 2008); c.405_406insCT, (Tajima et al 2009);c.214_217delGCACinsCA, c.221_ 236del16, (Dateki et al 2010)), leading to a truncated mRNA that was destined for degradation by the nonsense mediated RNA decay (c.93C[G; C.106dupC; c.252delC) or expected to be inactive due to loss of the transactivation domain. Indeed, functional analysis revealed these OTX2 mutations to be loss-of-function mutations (Chatelain et al 2006), with the exception of p.N225S.…”